An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA (R)) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-).

Trial Profile

An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA (R)) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-).

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs ERY-ASP (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2015 Results published in the September 2015 issue of the American Journal of Hematology, according to an ERYtech Pharma media release.
    • 17 Jun 2012 Results were presented at the 17th Congress of the European Haematology Association (EHA-2012), according to an ERYtech Pharma media release.
    • 17 Jun 2012 Status changed from active, no longer recruiting to completed, according to an ERYtech Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top